Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor, versus chemotherapy in patients with advanced UC that progr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2019-06, Vol.30 (6), p.970-976
Hauptverfasser:	Fradet, Y., Bellmunt, J., Vaughn, D.J., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Nam, K., Frenkl, T.L., Perini, R.F., de Wit, R., Bajorin, D.F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Docetaxel - administration & dosage Editor's Choice Follow-Up Studies Humans Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Original Paclitaxel - administration & dosage PD-1 PD-L1 pembrolizumab Prognosis Response Evaluation Criteria in Solid Tumors Survival Rate Urologic Neoplasms - drug therapy Urologic Neoplasms - pathology urothelial cancer Vinblastine - administration & dosage Vinblastine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!